Chinese innovative drug developers have been charting a new path to global expansion as they seek more diverse models to collaborate amid a sustained domestic capital shortage.
A growing number of companies are turning to the “NewCo” strategy — short for newly formed company, which involves partnering with foreign investment institutions to establish a new company overseas. Under this model, the Chinese firm licenses the international rights of their innovative drug candidates to the NewCo while retaining equity in the new entity.
京公网安备 11010502034662号 